Campaigners argue the new regulations are not extensive enough where the recommendation of...
Evaluating NICE guidelines in regards to cannabis-based medicinal products targeting pain
Campaigners argue the new regulations are not extensive enough where the recommendation of cannabis-based medicine for pain is concerned.
Biogen’s Phase II LILAC trial for lupus treatment meets goals
Biogen has reported that the Phase II LILAC clinical trial of BIIB059 has met the primary endpoints in patients with cutaneous lupus erythematosus (CLE) and systemic lupus erythematosus (SLE).
VFMCRP and ChemoCentryx report positive data for avacopan
Vifor Fresenius Medical Care Renal Pharma (VFMCRP) and ChemoCentryx have reported positive data from the Phase III clinical trial of avacopan to treat anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis.
Nektar and Alkermes data could translate into a resurgence of IL-2 agonists
Data for modified IL-2 selective receptor agonists, NKTR-214 and ALKS 4230, was presented at the 2019 Society for Immunotherapy of Cancer (SITC) conference.
Can anifrolumab become a breakthrough therapy for lupus patients?
Although anifrolumab met its primary endpoint in the TULIP-2 trial, it failed to meet a different primary endpoint in the Phase III TULIP-1 trial.
UCB reports positive data from BE READY trial of bimekizumab
UCB has reported positive results from the Phase III BE READY clinical trial of its investigational drug bimekizumab for the treatment of moderate-to-severe chronic plaque psoriasis in adults.
GSK reports positive data for Nucala in late-stage HES trial
GlaxoSmithKline (GSK) has reported positive data from a Phase III clinical trial of Nucala (mepolizumab) in patients suffering from hypereosinophilic syndrome (HES).
Novartis’ PREVENT trial of Cosentyx meets primary endpoint
Novartis has reported that the ongoing Phase III PREVENT clinical trial of Cosentyx (secukinumab) has met its primary endpoint in non-radiographic axial spondyloarthritis (nr-axSpA) patients.
AstraZeneca’s anifrolumab shows promise in trial for SLE
AstraZeneca has reported that anifrolumab reduced disease activity in the Phase III TULIP 2 study involving patients with moderate to severe systemic lupus erythematosus (SLE).
Janssen’s Tremfya meets primary endpoint in Discover studies
Janssen Pharmaceutical has reported positive data from the Phase III Discover-1 and Discover-2 clinical trials of Tremfya (guselkumab) in patients with active psoriatic arthritis (PsA).